Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04797286 · ClinicalTrials.gov registry record · Phase 2
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
A Phase 2 study of Scleroderma and Mildly Elevated Pulmonary Pressures, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT04797286 is a Phase 2 study of Scleroderma and Mildly Elevated Pulmonary Pressures that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 30 participants, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04797286, a Phase 2 study of Scleroderma and Mildly Elevated Pulmonary Pressures, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sildenafil
Study Locations (2)
Louisiana
- Louisiana State University - New Orleans
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04797286
The ClinicalTrials.gov registry entry for NCT04797286 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (93% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Scleroderma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04797286 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Louisiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT04797286 about?
NCT04797286 is a clinical study titled "Sildenafil for Early Pulmonary Vascular Disease in Scleroderma". This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
What is the current status of trial NCT04797286?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-09-20. Estimated completion is 2026-09-01.
What conditions does trial NCT04797286 study?
This clinical trial studies the following conditions: Scleroderma, Mildly Elevated Pulmonary Pressures.
What interventions are being tested in trial NCT04797286?
The interventions under investigation include: Placebo (OTHER), Sildenafil (DRUG).
Who is sponsoring clinical trial NCT04797286?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04797286 being conducted?
This trial has 2 study locations across Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
-
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
RECRUITING · Phase 2
-
Psychological Treatments for Scleroderma
COMPLETED · Phase 2
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.